Cancer immunotherapy
4 European H2020 organizations list this as part of their work.
Most active in this area
- OSPEDALE SAN RAFFAELE SRL
Milan research hospital with deep expertise in gene/cell therapy, liver immunology, and neurodegeneration — from bench research to clinical trials.
“Active in CAR-T therapy development (CARAMBA, EURE-CART, CARAT) and hepatocellular carcinoma immunology (FATE), combining cellular engineering with tumor immunology.”
IT77 projects - CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE
Major French university hospital contributing clinical neuroscience, immunotherapy trials, and hypothalamic research to large European health consortia.
“Participated in H2020MM04 (dendritic cell immunotherapy for mesothelioma) and CARAMBA (CAR T-cell therapy for multiple myeloma).”
FR17 projects - KLINIKUM DER UNIVERSITAET REGENSBURG
German university hospital specializing in transplantation immunology, kidney disease biomarkers, advanced cell therapies, and Europe's leading H2020 tinnitus research program.
“EN_ACTI2NG (CAR/TCR anti-cancer immunotherapy), PAVE (nanovaccine for pancreatic cancer), and INsTRuCT (myeloid cell therapy with oncology applications).”
DE13 projects - ALIRI FRANCE SAS
French biotech SME providing preclinical drug development and analytical services for tuberculosis, cancer, and autoimmune disease research consortia.
“CAPSTONE project covers immunotherapy, innate and adaptive immunity research for cancer treatment.”
SMEFR3 projects